Promising aHUS drug trial stalls after only 6 patients enrolled
NCT ID NCT03205995
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the study was terminated early and only enrolled 6 people, so we have very little information about how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
narsoplimab (a monoclonal antibody given by IV and daily injections)
What this could lead to
If successful, narsoplimab could offer a new treatment option for people with aHUS, potentially improving platelet counts and controlling the disease.
What could go wrong
The trial was terminated early with only 6 participants, so results are very limited. It is unclear if narsoplimab is safe or effective, and aHUS is a rare, serious condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Chicago, Illinois, 60643, United States
-
Omeros Investigational Site
Vilnius, Lithuania
-
Omeros Investigational Site
Lodz, Poland
-
Omeros Investigational Site
New Taipei City, Taiwan